Fluzone Available for 2012-2013 Influenza Season

FLUZONE (trivalent inactivated "split virus" influenza vaccine [Types A and B]) for IM inj by Sanofi
FLUZONE (trivalent inactivated "split virus" influenza vaccine [Types A and B]) for IM inj by Sanofi

Sanofi Pasteur announced that it has begun shipping the first lots of the 2012-2013 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).

In addition to two new virus strains that were recommended for this season's influenza vaccine formulation, Sanofi also announced that Fluzone and Fluzone High-Dose vaccines have a new syringe cap that does not contain latex.

Fluzone (22.5mcg/0.25mL dose) is indicated for children ≥6 months of age through adulthood. Fluzone High-Dose vaccine (180mcg/0.5mL dose) is indicated for adults ≥65 years of age. In addition, Fluzone Intradermal vaccine (27mcg/01.mL dose), which was introduced in 2011 with limited availability, will now be available for adults 18–64 years of age. This vaccine uses an ultra-fine needle that is 90% shorter than the typical needle used for intramuscular influenza vaccine.

Direct shipments to health care providers and distributors will be ongoing with health care providers who have placed reservations with Sanofi Pasteur receiving initial shipments by August and completed orders by the end of September.

For more information call (800) VACCINE or visit www.fluzone.com.